INSM · Insider Trading
Insmed, Inc.
Every open-market purchase and sale reported by INSM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-20 | Paul Hudson | Director | A | +6,139 | — |
| 2026-10-20 | Utpal Koppikar | Director | A | +6,139 | — |
| 2026-09-11 | David R Brennan | Director | Sell | −25,000 | −$3.10M |
| 2026-08-19 | Melvin Md Sharoky | Director | Sell | −5,000 | −$637.65K |
| 2026-08-12 | Roger Adsett | Chief Operating Officer | MIXED | — | −$27.06M |
| 2026-08-07 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | −$2.92M |
| 2026-07-24 | William Lewis | Chair and CEO | MIXED | — | −$868.02K |
| 2026-07-10 | William Lewis | Chair and CEO | MIXED | — | −$989.24K |
| 2026-07-08 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | −$1.04M |
| 2026-06-26 | William Lewis | Chair and CEO | MIXED | — | −$1.68M |
| 2026-06-24 | Michael Alexander Smith | Chief Legal Officer | Sell | −1,806 | −$173.05K |
| 2026-06-24 | Samuele Butera | SVP, GM, Global Respiratory | A | +7,342 | — |
| 2026-06-10 | William Lewis | Chair and CEO | Sell | −6,515 | −$612.61K |
| 2026-06-05 | Martina M.D. Flammer | Chief Medical Officer | Sell | −4,424 | −$455.25K |
| 2026-06-05 | William Lewis | Chair and CEO | Sell | −7,605 | −$777.76K |
| 2026-06-05 | Michael Alexander Smith | Chief Legal Officer | Sell | −2,159 | −$220.80K |
| 2026-06-05 | Sara Bonstein | Chief Financial Officer | Sell | −2,404 | −$245.86K |
| 2026-06-05 | Roger Adsett | Chief Operating Officer | Sell | −2,370 | −$242.38K |
| 2026-05-22 | Michael Alexander Smith | Chief Legal Officer | Sell | −6,149 | −$666.98K |
| 2026-05-20 | William Lewis | Chair and CEO | MIXED | −14,865 | −$2.45M |
| 2026-05-15 | William Lewis | Chair and CEO | Sell | −13,283 | −$1.54M |
| 2026-05-15 | Leo Lee | Director | A | +3,305 | — |
| 2026-05-15 | Clarissa Desjardins | Director | A | +3,305 | — |
| 2026-05-15 | David R Brennan | Director | A | +3,305 | — |
| 2026-05-15 | Melvin Md Sharoky | Director | A | +3,305 | — |
| 2026-05-15 | Michael Alexander Smith | Chief Legal Officer | Sell | −4,109 | −$477.38K |
| 2026-05-15 | Martina M.D. Flammer | Chief Medical Officer | Sell | −18,333 | −$2.13M |
| 2026-05-15 | Elizabeth M Anderson | Director | A | +3,305 | — |
| 2026-05-15 | Roger Adsett | Chief Operating Officer | Sell | −5,837 | −$678.14K |
| 2026-05-15 | Carol Schafer | Director | A | +3,305 | — |
| 2026-05-15 | Sara Bonstein | Chief Financial Officer | Sell | −8,272 | −$961.04K |
| 2026-05-13 | Martina M.D. Flammer | Chief Medical Officer | MIXED | — | −$1.08M |
| 2026-05-06 | William Lewis | Chair and CEO | MIXED | — | −$1.20M |
| 2026-04-17 | William Lewis | Chair and CEO | MIXED | — | −$1.27M |
| 2026-04-08 | William Lewis | Chair and CEO | MIXED | — | −$1.48M |
| 2026-04-03 | Roger Adsett | Chief Operating Officer | MIXED | — | −$13.22M |
| 2026-03-31 | Michael Alexander Smith | Chief Legal Officer | MIXED | — | −$2.48M |
| 2026-03-20 | William Lewis | Chair and CEO | MIXED | — | −$1.27M |
| 2026-03-05 | Melvin Md Sharoky | Director | G | −100 | — |
| 2026-03-05 | William Lewis | Chair and CEO | MIXED | — | −$1.30M |
| 2026-02-27 | Melvin Md Sharoky | Director | G | −100 | — |
| 2026-02-25 | David R Brennan | Director | G | −6,000 | — |
| 2026-02-25 | Michael Alexander Smith | Chief Legal Officer | MIXED | −4,526 | −$3.51M |
| 2026-02-23 | William Lewis | Chair and CEO | MIXED | — | −$1.35M |
| 2026-02-11 | William Lewis | Chair and CEO | MIXED | −2,697 | −$1.71M |
| 2026-02-11 | David W J McGirr | Director | G | — | — |
| 2026-02-06 | Martina M.D. Flammer | Chief Medical Officer | Sell | −869 | −$132.47K |
| 2026-02-04 | Martina M.D. Flammer | Chief Medical Officer | MIXED | −795 | −$833.22K |
| 2026-02-04 | Michael Alexander Smith | Chief Legal Officer | Sell | −640 | −$100.01K |
| 2026-02-04 | William Lewis | Chair and CEO | Sell | −3,009 | −$470.43K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William Lewis | Chair and CEO | 503,682 | $57.97M |
| Roger Adsett | Chief Operating Officer | 257,624 | $29.65M |
| Melvin Md Sharoky | Director | 251,504 | $28.94M |
| John Drayton Wise | Chief Commercial Officer | 140,935 | $16.22M |
| David R Brennan | Director | 99,238 | $11.42M |
| David W J McGirr | Director | 97,723 | $11.25M |
| Clarissa Desjardins | Director | 73,337 | $8.44M |
| Sara Bonstein | Chief Financial Officer | 69,082 | $7.95M |
| Carol Schafer | Director | 66,622 | $7.67M |
| Elizabeth M Anderson | Director | 62,034 | $7.14M |
| Martina M.D. Flammer | Chief Medical Officer | 60,486 | $6.96M |
| Leo Lee | Director | 57,971 | $6.67M |
| Orlov S Nicole Schaeffer | Chief People Strategy Officer | 41,754 | $4.81M |
| Michael Alexander Smith | Chief Legal Officer | 37,648 | $4.33M |
| Samuele Butera | SVP, GM, Global Respiratory | 7,342 | $844.95K |
| Utpal Koppikar | Director | 6,139 | $706.51K |
| Paul Hudson | Director | 6,139 | $706.51K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INSM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.